Proteothera, Inc. Announces Scientific Advisors to Aid in Development of Novel Therapy for Acute Gout Attacks

Share Article

ProteoThera, Inc., an early stage biotech platform company that is developing therapies for the local delivery of validated and FDA approved drugs, peptides, and small molecules to treat autoinflammatory diseases and tissue regeneration, today announced the team of scientific advisors who will guide the Company with their development of local delivery of a modified IL-1RA for the relief of pain for patients suffering from acute gout attacks.

News Image
“I believe that ProteoThera may be changing the paradigm for the traditional treatment of acute gout flares by potentially offering a safe and effective treatment for acute gout with an early onset of pain relief.” said Dr. Lee Simon

ProteoThera, Inc., an early stage biotech platform company that is developing therapies for the local delivery of validated and FDA approved drugs, peptides, and small molecules to treat autoinflammatory diseases and tissue regeneration, today announced the team of scientific advisors who will guide the Company with their development of local delivery of a modified IL-1RA for the relief of pain for patients suffering from acute gout attacks.

“I believe that ProteoThera may be changing the paradigm for the traditional treatment of acute gout flares by potentially offering a safe and effective treatment for acute gout with an early onset of pain relief,” said Dr. Lee Simon, who serves as the Company’s acting Medical Director and lead scientific advisor. “The compilation of these renowned gout experts to serve as advisors for the acute gout therapy development program is a great step towards that goal.”

Advisors to ProteoThera’s acute gout therapy development program include the following experts:

  •     Lee Simon, M.D., Principal, SDG LLC, Former FDA Division Director, Division of Pulmonary, Allergy and Rheumatology Products
  •     Robert Terkeltaub, M.D., Professor of Medicine, University of California, San Diego
  •     Naomi Schlesinger, M.D., Professor of Medicine, Chief of Rheumatology, Rutgers University
  •     Joseph Flood, M.D., Columbus Arthritis Center

“We warmly welcome our new scientific advisors to the ProteoThera team,” said Patrick O’Donnell, President and Chief Executive Officer of ProteoThera. “I am confident that under guidance from this group of leaders in rheumatology with such varied foundations of expertise, our company will make great strides in furthering the development of our lead therapy and further prove out the significant value of our matrix-binding peptide technology platform for the local delivery of numerous commercially validated therapeutics.”

About ProteoThera, Inc.
ProteoThera, Inc. is an early stage biotechnology company that is advancing drug targeting technology. The Company's transformative platform technology, a proprietary tissue matrix-binding (MB) peptide technology, is being developed to improve clinical efficacy and safety of FDA approved and validated therapeutics to create a new paradigm in the treatment of autoinflammatory diseases and in tissue regeneration.

The MB targeting technology was developed at Brigham and Women’s Hospital and Harvard Medical School. The MB technology can generate new pharmacokinetic profiles for therapies, transforming systemically delivered drugs into locally or subcutaneous delivered proteins, peptides, and small molecules. ProteoThera’s focus on previously validated or approved therapies greatly de-risks the clinical, regulatory, and commercial pathways. By keeping therapies where they are needed to enable therapeutic effect, the MB platform may also improve the safety profile by reducing or eliminating side effects associated with whole-body systemic exposure.

ProteoThera’s first development priority is the use of PRT-1000 (MB - Interleukin 1 Receptor Antagonist (MB-IL1RA) for treatment of acute gout pain. IL1RA is a potent cytokine inhibitor, already FDA approved for systemic administration in rheumatoid arthritis. Gout is a large and growing market with total gout drug sales projected to double to more than $2 Billion by 2018 in the US and Europe.
###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Patrick ODonnell
Visit website